CD73 is an ectoenzyme that generates extracellular adenosine, a key modulator suppressing the immune response. Tumors that overexpress CD73 are protected from immune attack. CD73 blocking antibodies stimulate anti-tumor immunity and enhance the efficacy of approved cancer immunotherapies, including PD1 and CTLA4 therapies, in preclinical models.
Surface is developing a best-in-class, fully human CD73 antibody with the potential to treat a wide range of cancer types. Our antibodies inhibit CD73 enzymatic activity and reduce adenosine accumulation in tumors, allowing immune cells to detect and destroy cancer cells.